UY28458A1 - Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos - Google Patents

Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos

Info

Publication number
UY28458A1
UY28458A1 UY28458A UY28458A UY28458A1 UY 28458 A1 UY28458 A1 UY 28458A1 UY 28458 A UY28458 A UY 28458A UY 28458 A UY28458 A UY 28458A UY 28458 A1 UY28458 A1 UY 28458A1
Authority
UY
Uruguay
Prior art keywords
compounds
treatment
neurodegenerative disorders
formula
oxazol
Prior art date
Application number
UY28458A
Other languages
English (en)
Inventor
Yuhpyng L Chen
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY28458A1 publication Critical patent/UY28458A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

La presente invención se refiere a compuestos de Fórmula en donde R3, R5, R7 y Z, así como otros valores enumerados con relación a R3, R5, R6, R7 y Z son como se los define. Loscompuestos de Fórmula I presentan actividad inhibidora de la producción de péptido AB. Esta invención se refiere además a composiciones farmacéuticas y métodos para tratar enfermedades, por ejemplo, enfermedades neurodegenerativas, i.e. enfermedad de Alzheimer, en un mamífero, que comprende compuestos de Fórmula I.
UY28458A 2003-08-06 2004-08-06 Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos UY28458A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49288403P 2003-08-06 2003-08-06
US49802803P 2003-08-27 2003-08-27

Publications (1)

Publication Number Publication Date
UY28458A1 true UY28458A1 (es) 2005-03-31

Family

ID=34197958

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28458A UY28458A1 (es) 2003-08-06 2004-08-06 Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos

Country Status (13)

Country Link
US (1) US7112599B2 (es)
EP (1) EP1653952A4 (es)
JP (1) JP2007501244A (es)
AR (1) AR046327A1 (es)
BR (1) BRPI0413349A (es)
CA (1) CA2534529A1 (es)
MX (1) MXPA06001480A (es)
PA (1) PA8608601A1 (es)
PE (1) PE20050337A1 (es)
SV (1) SV2005001840A (es)
TW (1) TW200510351A (es)
UY (1) UY28458A1 (es)
WO (1) WO2005016267A2 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50595B (sr) * 2004-03-23 2010-05-07 Pfizer Products Incorporated Jedinjenja imidazola za lečenje neurodegenerativnih poremećaja
US20050222227A1 (en) * 2004-04-01 2005-10-06 Pfizer Inc Oxazole-amine compounds for the treatment of neurodegenerative disorders
EP1940802A2 (en) * 2005-09-22 2008-07-09 Pfizer Products Inc. Imidazole compounds for the treatment of neurological disorders
KR101335845B1 (ko) 2007-02-15 2013-12-02 에프. 호프만-라 로슈 아게 Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
DK2385938T3 (en) 2009-01-12 2015-04-27 Pfizer Ltd Sulfonamidderivater
EA201791271A1 (ru) * 2012-05-31 2018-01-31 Фенекс Фармасьютикалз Аг ТИАЗОЛЫ, ЗАМЕЩЕННЫЕ КАРБОКСАМИДОМ ИЛИ СУЛЬФОНАМИДОМ, И РОДСТВЕННЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ МОДУЛЯТОРОВ ДЛЯ ОРФАННОГО ЯДЕРНОГО РЕЦЕПТОРА RORγ
EP3768269A4 (en) * 2018-03-23 2022-03-23 Yumanity Therapeutics, Inc. COMPOUNDS AND THEIR USES
CN113651805B (zh) * 2021-07-19 2023-07-25 安徽医科大学 一种1,2,4-噁二唑-吡啶类化合物及其在治疗阿尔茨海默症中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3094462A (en) * 1961-09-18 1963-06-18 Mcneilab Inc Therapeutic reaction complex for muscle relaxation
US3591584A (en) * 1968-08-27 1971-07-06 Pfizer Benzothiazine dioxides
GB1264258A (es) * 1970-10-10 1972-02-16
GB9320660D0 (en) * 1993-10-07 1993-11-24 British Bio Technology Inhibition of cytokine production
KR20000005291A (ko) * 1996-06-25 2000-01-25 다케다 야쿠힌 고교 가부시키가이샤 옥사졸론 유도체 및 항-헬리코박터 파일로리 제제로서의 이의용도
US20020002199A1 (en) * 1998-03-12 2002-01-03 Lone Jeppesen Modulators of protein tyrosine phosphatases (ptpases)
WO2000059285A2 (en) * 1999-04-02 2000-10-12 Du Pont Pharmaceuticals Company NOVEL LACTAM INHIBITORS OF MATRIX METALLOPROTEINASES, TNF-α, AND AGGRECANASE
TW593241B (en) * 1999-04-20 2004-06-21 Hoffmann La Roche Carbamic acid derivatives
AR039059A1 (es) * 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
CN1688557A (zh) * 2002-10-09 2005-10-26 辉瑞产品公司 用于治疗神经变性疾病的噻唑化合物
CA2501799C (en) * 2002-10-09 2008-06-17 Pfizer Products Inc. Pyrazole compounds for treatment of neurodegenerative disorders
AU2003298195B8 (en) * 2002-12-23 2009-04-23 F. Hoffmann-La Roche Ag Oxazoles as mGluR1 enhancer
PL378343A1 (pl) * 2003-01-13 2006-03-20 F. Hoffmann-La Roche Ag Pochodne benzoksazolu i ich zastosowanie jako ligandów receptora adenozyny

Also Published As

Publication number Publication date
WO2005016267A2 (en) 2005-02-24
AR046327A1 (es) 2005-12-07
PA8608601A1 (es) 2005-03-03
PE20050337A1 (es) 2005-06-06
JP2007501244A (ja) 2007-01-25
CA2534529A1 (en) 2005-02-24
MXPA06001480A (es) 2006-05-15
EP1653952A4 (en) 2007-04-04
BRPI0413349A (pt) 2006-10-10
US20050032859A1 (en) 2005-02-10
SV2005001840A (es) 2005-11-04
EP1653952A2 (en) 2006-05-10
WO2005016267A3 (en) 2005-04-21
US7112599B2 (en) 2006-09-26
TW200510351A (en) 2005-03-16

Similar Documents

Publication Publication Date Title
DOP2005000040A (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
UY28450A1 (es) Compuestos heteroarilo de 6 miembros para el tratamiento de trastornos neurodegenerativos.
ECSP055719A (es) Compuestos de tiazol para el tratamiento de trastornos neurodegenerativos
UY28484A1 (es) Compuestos para el tratamiento de trastornos neurodegenerativos
DOP2005000049A (es) Compuestos de sulfonamidas para el tratamiento de trastornos neurodegererativos
UY28280A1 (es) 2- hidroxi - 3- diaminoalcanos de benzamida
BR0315158A (pt) Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
UY28279A1 (es) Fenacilo 2 -hidroxi - 3 - diaminoalcanos
BRPI0509504A (pt) compostos de tiadiazol-amina para o tratamento de distúrbios neurodegenerativos
MXPA05012196A (es) Compuestos de isoxazol e isotiazol para el tratamiento de trastornos neurodegenerativos.
CR9815A (es) Compuestos de imidazol para el tratamiento de transtornos neurologicos
ATE402150T1 (de) Pyrazolaminverbindungen zur behandlung neurodegenerativer erkrankungen
UY28458A1 (es) Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos
BR0306855A (pt) Método para o tratamento de distúrbios cognitivos
DOP2004000970A (es) Compuestos de oxazol para el tratamiento de trastornos neurodegenerativos
DOP2004000982A (es) Compuestos para el tratamiento de trastornos neurodegenerativos
DOP2004000966A (es) Compuestos heteroarilo de 6 miembros para el tratamiento de trastornos neurodegenerativos
DOP2006000200A (es) Compuestos de imidazol para el tratamiento de trastonos neurologicos
CU23591B7 (es) Compuestos de imidazol para el tratamiento de desórdenes neurovegetativos
BRPI0402756A (pt) método para o tratamento de distúrbios cognitivos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150604